Pharmaceuticals

Myelodysplastic Syndrome Drugs Market to Reach $3.48 Billion by 2029, Growing at a CAGR of 9.3%

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Myelodysplastic Syndrome Drugs Industry Expected To Reach By 2029, Starting From 2025 Levels?

The myelodysplastic syndrome drugs market size has demonstrated robust growth in recent years. It is anticipated to expand from $2.25 billion in 2024 to $2.44 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. Historically, this expansion has been driven by factors such as an aging population, advancements in diagnostics, chemotherapy-related MDS cases, an increase in cancer survivors, and continuous clinical research and drug development efforts.

The myelodysplastic syndrome drugs market is projected to experience robust expansion over the coming years. This market is set to reach $3.48 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.3%. Key drivers for this growth during the forecast period include an expanding elderly population, progress in targeted treatments, enhanced comprehension of disease pathways, increased recognition leading to earlier detection, and the broadening scope of oncology research. Significant trends anticipated in the forecast period encompass the optimization of erythropoiesis-stimulating agents, the adoption of combination therapies, a heightened emphasis on iron chelation therapy, the impact of regulatory approvals and market access, and the evolution of patient-centric care models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp

Which Industry Drivers Are Expected To Accelerate The Myelodysplastic Syndrome Drugs Market From 2025 To 2029?

The rising occurrence of myelodysplastic syndrome is projected to drive expansion in the myelodysplastic syndrome drug market in the forthcoming years. Myelodysplastic syndrome (MDS) refers to a collection of conditions marked by irregular development and maturation of blood cells within the bone marrow. This condition is a form of blood cancer that principally impairs the generation of healthy blood cells. Medications for myelodysplastic syndrome are utilized to manage the condition, comprising drugs that either suppress or regulate the immune system, thereby reducing the necessity for red blood cell transfusions. For example, as reported by the US-based American Journal of Managed Care in October 2022, the estimated prevalence of myelodysplastic syndrome within the USA ranges from 60,000 to 175,000 cases. Consequently, a rise in myelodysplastic syndrome incidences is fueling the expansion of the myelodysplastic syndrome drug market.

What Are The Major Segment Categories Driving The Myelodysplastic Syndrome Drugs Market Growth?

The myelodysplastic syndrome drugs market covered in this report is segmented –

1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics

2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts

3) By Route of Administration: Oral, Parenteral

4) By Applications: Original, Generics

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide

2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine

3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products

What Trends Are Expected To Drive The Myelodysplastic Syndrome Drugs Market?

Companies operating within the myelodysplastic syndrome drugs market are developing telomerase inhibitors, which are designed to target the telomerase enzyme. This approach aims to slow the progression of the disease by limiting the uncontrolled division of abnormal cells. These inhibitors are beneficial in myelodysplastic syndrome treatments as they function by impeding the telomerase enzyme, thereby reducing the proliferation of abnormal cells and potentially improving patient outcomes. For instance, in June 2024, Geron Corporation, a US-based biotechnology company, introduced rytelo (imetelstat). This FDA-approved intravenous telomerase inhibitor is intended for adults with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia that is unresponsive to or ineligible for ESA. Rytelo offers durable transfusion independence and improved hemoglobin levels, thus addressing an unmet need in the myelodysplastic syndrome drugs market while presenting a manageable safety profile.

Which Leading Players Are Enhancing Their Myelodysplastic Syndrome Drugs Market Presence Worldwide?

Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Myelodysplastic Syndrome Drugs Market?

North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Myelodysplastic Syndrome Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10675&type=smp

Browse Through More Reports Similar to the Global Myelodysplastic Syndrome Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795